The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Meso Scale Diagnostics sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Meso Scale Diagnostics LLC, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

Meso Scale Diagnostics LLC (MSD) is a developer, manufacturer and commercializer of biomarker assays and instruments. The company offers instruments for the measurement of molecules in biological samples, cytokines and phosphoproteins. Its products includes angiogenesis and vascular assay kits, bone metabolism assay kits, cytokine and chemokine assay kits, inflammation assay kits, intracellular signaling assay kits, neurodegeneration assay kits, toxicology assay kits, immunoassay plates, and reagents. MSD offers services including assay development, biomarker services, custom conjugation, instrument services and warranties and prototype printing. The company’s products find applications in clinical immunology, intracellular signaling, oncology and cancer, metabolic neurodegeneration, fertility and assay development, among others. It serves pharmaceutical companies, government institutions, universities, and clinical laboratories. MSD is headquartered in Rockville, Maryland, the US.

The key metrics of Meso Scale Diagnostics related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As Meso Scale Diagnostics is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Meso Scale Diagnostics.

For a detailed understanding of the performance of Meso Scale Diagnostics, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.